Programmed death-1 (PD-1, CD279), an inhibitory co-stimulatory molecule of the CD28 superfamily, plays a critical role in immune response. In this report, four novel mouse anti-human PD-1 monoclonal antibodies (MAbs) were prepared using hybridoma technology and immunological characteristics of the MAbs were determined. The results showed that all the MAbs (clones 9H1, 4B9, 8F5, and 1F8) were IgG1(κ) and bound specifically to human PD-1. By mutual competition, we found that the antibodies recognized three different epitopes of PD-1 antigen and 9H1 MAb could block both PD-1/PD-L1 and PD-1/PD-L2 interaction. Cross-linking of PD-1 with MAb 9H1 markedly blocked PD-1 negative signal and promoted T cell proliferation. In addition, 4B9 and 9H1 MAbs were suitable for indirect ELISA detection. Thus, the MAbs against human PD-1 with high specificity and different activity would be useful for the further study of this molecule.
Get full access to this article
View all access options for this article.
References
1.
LanzavecchiaA, LezziG, ViolaA. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell, 1999; 96:1–4.
2.
LenschowDJ, WalunasTL, BluestoneJA. CD28/B7 system of T cell costimulation. Annu Rev Immunol, 1996; 14:233–258.
WatanabeN, GavrieliM, SedyJR, YangJ, FallarinoF, LoftinSK, HurchlaMA, ZimmermanN, SimJ, ZangX, MurphyTL, RussellJH, AllisonJP, MurphyKM. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol, 2003; 4:670–679.
5.
CarterL, FouserLA, JussifJ, FitzL, DengB, WoodCR, CollinsM, HonjoT, FreemanGJ, CarrenoBM. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol, 2002; 32:634–643.
6.
BrownJA, DorfmanDM, MaFR, SullivanEL, MunozO, WoodCR, GreenfieldEA, FreemanGJ. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol, 2003; 170:1257–1266.
7.
KuipersH, MuskensF, WillartM, HijdraD, van AssemaFB, CoyleAJ, HoogstedenHC, LambrechtBN. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol, 2006; 36:2472–2482.
8.
IshidaY, AgataY, ShibaharaK, HonjoT. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J, 1992; 11:3887–3895.
9.
ChemnitzJM, ParryRV, NicholsKE, JuneCH, RileyJL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol, 2004; 173:945–954.
10.
DongH, ZhuG, TamadaK, ChenL. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999; 5:1365–1369.
11.
LatchmanY, WoodCR, ChernovaT, ChaudharyD, BordeM, ChernovaI, IwaiY, LongAJ, BrownJA, NunesR, GreenfieldEA, BourqueK, BoussiotisVA, CarterLL, CarrenoBM, MalenkovichN, NishimuraH, OkazakiT, HonjoT, SharpeAH, FreemanGJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol, 2001; 2:261–268.
12.
FreemanGJ, LongAJ, IwaiY, BourqueK, ChernovaT, NishimuraH, FitzLJ, MalenkovichN, OkazakiT, ByrneMC, HortonHF, FouserL, CarterL, LingV, BowmanMR, CarrenoBM, CollinsM, WoodCR, HonjoT. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 2000; 192:1027–1034.
13.
BlankC, BrownI, MarksR, NishimuraH, HonjoT, GajewskiTF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol, 2003; 171:4574–4581.
ZhuB, GuleriaI, KhosroshahiA, ChitnisT, ImitolaJ, AzumaM, YagitaH, SayeghMH, KhourySJ. Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol, 2006; 176:3480–3489.
16.
TrabattoniD, SaresellaM, PaceiM, MarventanoI, MendozziL, RovarisM, CaputoD, BorelliM, ClericiM. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol, 2009; 183:4984–4993.
17.
DongH, StromeSE, MattesonEL, ModerKG, FliesDB, ZhuG, TamuraH, DriscollCL, ChenL. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest, 2003; 111:363–370.
IwaiY, IshidaM, TanakaY, OkazakiT, HonjoT, MinatoN. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA, 2002; 99:12293–12297.
20.
WongRM, ScotlandRR, LauRL, WangC, KormanAJ, KastWM, WeberJS. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol, 2007; 19:1223–1234.
IwaiY, OkazakiT, NishimuraH, KawasakiA, YagitaH, HonjoT. Microanatomical localization of PD-1 in human tonsils. Immunol Lett, 2002; 83:215–220.
23.
GodfreyWR, SpodenDJ, GeYG, BakerSR, LiuB, LevineBL, JuneCH, BlazarBR, PorterSB. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood, 2005; 105:750–758.
24.
ZhangJY, ZhangZ, WangX, FuJL, YaoJ, JiaoY, ChenL, ZhangH, WeiJ, JinL, ShiM, GaoGF, WuH, WangFS. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood, 2007; 109:4671–4678.
25.
BergerR, Rotem-YehudarR, SlamaG, LandesS, KnellerA, LeibaM, Koren-MichowitzM, ShimoniA, NaglerA. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res, 2008; 14:3044–3051.
26.
QiuYH, SunZW, ShiQ, SuCH, ChenYJ, ShiYJ, TaoR, GeY, ZhangXG. Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28. Cell Immunol, 2005; 236:154–160.
27.
WangQ, ChenY, XieF, GeY, WangX, ZhangX. A novel agonist anti-human OX40L monoclonal antibody that stimulates T cell proliferation and enhances cytokine secretion. Hybridoma, 2009; 28:269–276.
28.
WattsTH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol, 2005; 23:23–68.
29.
GreenwaldRJ, FreemanGJ, SharpeAH. The B7 family revisited. Annu Rev Immunol, 2005; 23:515–548.
30.
HamanishiJ, MandaiM, IwasakiM, OkazakiT, TanakaY, YamaguchiK, HiguchiT, YagiH, TakakuraK, MinatoN, HonjoT, FujiiS. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA, 2007; 104:3360–3365.
31.
ZhangL, GajewskiTF, KlineJ. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood, 2009; 114:1545–1552.
32.
OkudairaK, HokariR, TsuzukiY, OkadaY, KomotoS, WatanabeC, KuriharaC, KawaguchiA, NagaoS, AzumaM, YagitaH, MiuraS. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol, 2009; 35:741–749.
33.
DayCL, KaufmannDE, KiepielaP, BrownJA, MoodleyES, ReddyS, MackeyEW, MillerJD, LeslieAJ, DePierresC, MncubeZ, DuraiswamyJ, ZhuB, EichbaumQ, AltfeldM, WherryEJ, CoovadiaHM, GoulderPJ, KlenermanP, AhmedR, FreemanGJ, WalkerBD. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 2006; 443:350–354.
34.
ChenL, ZhangZ, ChenW, ZhangZ, LiY, ShiM, ZhangJ, ChenL, WangS, WangFS. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol, 2007; 178:6634–6641.
35.
DottiG. Blocking PD-1 in cancer immunotherapy. Blood, 2009; 114:1457–1458.
